Skip to main content
SpringerLink
Log in

Angiogenesis Inhibitors

  • Living reference work entry
  • First Online:
Encyclopedia of Inflammatory Diseases

  • 996 Accesses

Synonyms

Angiogenesis; Angiogenic regulators; Anti-angiogenic drugs; Inflammation; Tumor

Definition

Angiogenesis, the formation of new blood vessels from preexisting capillaries is an essential process during embryogenesis, wound healing, and female reproductive cycle. However, uncontrolled angiogenesis contributes to a number of pathological conditions. Excessive angiogenesis augments tumor formation, inflammation, sepsis, asthma, and psoriasis. Laboratory studies have shown that angiogenic inhibitors can be used for the treatment of excessive angiogenesis. In light of these studies, a number of anti-angiogenic drugs, which have been developed for cancer and inflammation, are either approved or are in the clinical stage of development. In this review, the potential and limitations of these anti-angiogenic drugs are discussed.

Physiology of Angiogenesis

Angiogenesis is the formation of new blood vessels from existent microvessels. As the human body grows, the cell number increases and...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Adams, V. R., & Leggas, M. (2007). Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clinical Therapeutics, 29(7), 1338–1353.

    Article  CAS  PubMed  Google Scholar 

  • Barrios, C. H., Liu, M. C., et al. (2010). Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Research and Treatment, 121(1), 121–131.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Bullock, A. J., Zhang, L., O’Neill, A. M., Percy, A., Sukhatme, V., Mier, J. W., Atkins, M. B., & Bhatt, R. S. (2010). Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). Journal of Clinical Oncology, 28, 4630.

    Article  Google Scholar 

  • Burstein, H. J., Elias, A. D., et al. (2008). Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology, 26(11), 1810–1816.

    Article  CAS  PubMed  Google Scholar 

  • Carmeliet, P. (2003). Angiogenesis in health and disease. Nature Medicine, 9(6), 653–660.

    Article  CAS  PubMed  Google Scholar 

  • Carmeliet, P., & Collen, D. (1998). Vascular development and disorders: Molecular analysis and pathogenic insights. Kidney International, 53(6), 1519–1549.

    Article  CAS  PubMed  Google Scholar 

  • Citti, L., & Rainaldi, G. (2005). Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Current Gene Therapy, 5(1), 11–24.

    Article  CAS  PubMed  Google Scholar 

  • Escudier, B., Eisen, T., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine, 356(2), 125–134.

    Article  CAS  PubMed  Google Scholar 

  • Fine, H. A., Figg, W. D., et al. (2000). Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. Journal of Clinical Oncology, 18(4), 708–715.

    CAS  PubMed  Google Scholar 

  • Gridelli, C., Morgillo, F., et al. (2011). Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study. Annals of Oncology, 22(7), 1528–1534.

    Article  CAS  PubMed  Google Scholar 

  • Gutierrez-Rodriguez, O. (1984). Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis and Rheumatism, 27(10), 1118–1121.

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz, H. (2004). Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clinical Colorectal Cancer, 4(Suppl 2), S62–S68.

    Article  CAS  PubMed  Google Scholar 

  • Joensuu, H., De Braud, F., et al. (2008). Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Annals of Oncology, 19(1), 173–177.

    Article  CAS  PubMed  Google Scholar 

  • Joensuu, H., De Braud, F., et al. (2011). Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: Final results of a phase II study. British Journal of Cancer, 104(11), 1686–1690.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kumar, S., Gertz, M. A., et al. (2003). Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clinic Proceedings, 78(1), 34–39.

    Article  PubMed  Google Scholar 

  • Larsson, H. (1990). Treatment of severe colitis in Behcet’s syndrome with thalidomide (CG-217). Journal of Internal Medicine, 228(4), 405–407.

    Article  CAS  PubMed  Google Scholar 

  • Llovet, J. M., Ricci, S., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378–390.

    Article  CAS  PubMed  Google Scholar 

  • Mita, A. C., Takimoto, C. H., et al. (2010). Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clinical Cancer Research, 16(11), 3044–3056.

    Article  CAS  PubMed  Google Scholar 

  • Morrow, P. K., Murthy, R. K., et al. (2012). An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer. Cancer, 118(17), 4098–4104.

    Article  CAS  PubMed  Google Scholar 

  • Nakayama, T., Yao, L., et al. (2004). Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. Journal of Clinical Investigation, 114(9), 1317–1325.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Petrillo, M., Scambia, G., et al. (2012). Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opinion on Investigational Drugs, 21(4), 451–472.

    Article  CAS  PubMed  Google Scholar 

  • Puri, M. C., Rossant, J., et al. (1995). The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO Journal, 14(23), 5884–5891.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Reck, M., von Pawel, J., et al. (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. Journal of Clinical Oncology, 27(8), 1227–1234.

    Article  CAS  PubMed  Google Scholar 

  • Rini, B. I., Wilding, G., et al. (2009). Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of Clinical Oncology, 27(27), 4462–4468.

    Article  CAS  PubMed  Google Scholar 

  • Rini, B. I., Escudier, B., et al. (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet, 378(9807), 1931–1939.

    Article  CAS  PubMed  Google Scholar 

  • Sandler, A., Gray, R., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 355(24), 2542–2550.

    Article  CAS  PubMed  Google Scholar 

  • Sato, T. N., Tozawa, Y., et al. (1995). Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 376(6535), 70–74.

    Article  CAS  PubMed  Google Scholar 

  • Stoeltzing, O., Ahmad, S. A., et al. (2003). Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Research, 63(12), 3370–3377.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sutton Arthritis Research Laboratory, Kolling Institute of Medical Research, The University of Sydney, 2065, St Leonards, Australia

    Nikita Minhas, Chris John Jackson & Meilang Xue

Authors
  1. Nikita Minhas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris John Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meilang Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meilang Xue .

Editor information

Editors and Affiliations

  1. Inst of Clinical Pharmacology Haus 74/75, JW Goethe University Frankfurt Fraunhofer IME, Frankfurt, Germany

    Michael Parnham

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Basel

About this entry

Cite this entry

Minhas, N., Jackson, C.J., Xue, M. (2013). Angiogenesis Inhibitors. In: Parnham, M. (eds) Encyclopedia of Inflammatory Diseases. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-0620-6_5-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-0620-6_5-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Birkhäuser, Basel

  • Online ISBN: 978-3-0348-0620-6

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation